Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XTNT Stock Forecast 2026-2027
$0.45
Current Price
$64.34M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XTNT Price Targets
+235.7%
To High Target of $1.50
+168.6%
To Median Target of $1.20
+123.8%
To Low Target of $1.00
XTNT Price Momentum
+7.1%
1 Week Change
0.0%
1 Month Change
-22.4%
1 Year Change
-42.3%
Year-to-Date Change
-53.0%
From 52W High of $0.95
+14.6%
From 52W Low of $0.39
📊 TOP ANALYST CALLS
Did XTNT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xtant Medical is one of their latest high-conviction picks.
Latest XTNT Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, XTNT has a bullish consensus with a median price target of $1.20 (ranging from $1.00 to $1.50). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $0.45, the median forecast implies a 168.6% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XTNT Analyst Ratings
3
Buy
0
Hold
0
Sell
XTNT Price Target Range
Low
$1.00
Average
$1.20
High
$1.50
Current: $0.45
Latest XTNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XTNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Mar 31, 2026 | BTIG | Buy | Maintains | $N/A | |
| Nov 11, 2025 | BTIG | Buy | Maintains | $N/A | |
| May 16, 2024 | BTIG | Buy | Maintains | $N/A | |
| Dec 5, 2023 | BTIG | Buy | Initiates | $N/A | |
| Jul 11, 2023 | Craig-Hallum | Buy | Maintains | $N/A | |
| Apr 26, 2023 | Craig-Hallum | Buy | Initiates | $N/A | |
| May 17, 2019 | Maxim Group | Hold | Downgrade | $N/A | |
| Dec 8, 2016 | Maxim Group | Buy | Initiates | $N/A | |
| Nov 30, 2016 | Aegis Capital | Buy | Initiates | $N/A |
Xtant Medical Holdings Inc. (XTNT) Competitors
The following stocks are similar to Xtant Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xtant Medical Holdings Inc. (XTNT) Financial Data
Xtant Medical Holdings Inc. has a market capitalization of $64.34M with a P/E ratio of 41.8x. The company generates $121.91M in trailing twelve-month revenue with a 1.5% profit margin.
Revenue growth is -36.5% quarter-over-quarter, while maintaining an operating margin of -14.0% and return on equity of +3.9%.
Valuation Metrics
Market Cap
$64.34M
Enterprise Value
$62.20M
P/E Ratio
41.8x
PEG Ratio
0.0x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
-36.5%
Gross Margin
+57.3%
Operating Margin
-14.0%
Net Margin
+1.5%
EPS Growth
-36.5%
Financial Health
Cash/Price Ratio
+19.5%
Current Ratio
3.3x
Debt/Equity
31.8x
ROE
+3.9%
ROA
+2.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xtant Medical Holdings Inc. (XTNT) Business Model
About Xtant Medical Holdings Inc.
What They Do
Develops and distributes regenerative medical devices.
Business Model
Xtant Medical Holdings generates revenue by developing and distributing innovative regenerative medicine products and surgical implants targeted at orthopedic and neurological surgery. The company serves hospitals, surgical centers, and clinics, providing essential solutions that enhance patient care and recovery, thereby creating a consistent demand for its products.
Additional Information
Xtant Medical's focus on advancing medical technology positions it as a significant player in the healthcare industry, particularly in the spine and orthopedics market. Their offerings include biologics and advanced materials that are crucial for treating complex injuries, highlighting the company's commitment to improving patient outcomes.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
217
CEO
Mr. Sean E. Browne
Country
United States
IPO Year
2015
Website
xtantmedical.comXtant Medical Holdings Inc. (XTNT) Latest News & Analysis
Latest News
Xtant Medical Q1 Earnings Call Highlights
2 months ago
Quick Summary
Xtant Medical (NYSEAMERICAN: XTNT) raised its 2026 revenue guidance after entering the hemostatic agent market but reported a decline in Q1 revenue due to divestitures and lost licenses.
Why It Matters
Xtant Medical's revenue guidance boost signals growth potential in a new market, despite Q1 declines, indicating strategic shifts that could affect future profitability and stock performance.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
Xtant Medical Holdings, Inc. (XTNT) held its Q1 2026 earnings call, providing insights into its financial performance and future outlook. Details from the call are available for investor review.
Why It Matters
Xtant Medical's Q1 2026 earnings reveal financial health, growth potential, and operational performance, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings raises 2026 revenue guidance to $101-$105 million, strengthens its balance sheet, and enters an exclusive U.S. distribution deal for Dilon Technologies' HEMOBLAST® product.
Why It Matters
Increased revenue guidance and a strengthened balance sheet signal growth potential. The exclusive distribution agreement enhances market position, likely boosting investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. (NYSE: XTNT) will release its Q1 2026 financial results on May 13, 2026, before market opening.
Why It Matters
Xtant Medical's upcoming financial results release could impact stock performance and investor sentiment, providing insights into its growth and operational efficiency in the orthopedic market.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings launched Trivium™ Shaped, a new pre-shaped bone graft product for spinal and orthopedic surgeries, expanding its Trivium™ portfolio.
Why It Matters
The launch of Trivium™ Shaped enhances Xtant Medical's product offerings, potentially increasing revenue and market share in the orthopedic sector, which can positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant has engaged Dilon's U.S. sales team to promote its HEMOBLAST® Bellows product, targeting the $2.0 billion global hemostatic products market.
Why It Matters
Xtant's partnership with Dilon's sales team enhances its market reach for HEMOBLAST® Bellows, targeting a significant $2 billion market, potentially driving revenue growth and investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XTNT Stock
What is Xtant Medical Holdings Inc.'s (XTNT) stock forecast for 2027?
Based on our analysis of 1 Wall Street analysts, Xtant Medical Holdings Inc. (XTNT) has a median price target of $1.20. The highest price target is $1.50 and the lowest is $1.00.
Is XTNT stock a good investment in 2027?
According to current analyst ratings, XTNT has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XTNT stock?
Wall Street analysts predict XTNT stock could reach $1.20 in the next 12 months. This represents a 168.6% increase from the current price of $0.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xtant Medical Holdings Inc.'s business model?
Xtant Medical Holdings generates revenue by developing and distributing innovative regenerative medicine products and surgical implants targeted at orthopedic and neurological surgery. The company serves hospitals, surgical centers, and clinics, providing essential solutions that enhance patient care and recovery, thereby creating a consistent demand for its products.
What is the highest forecasted price for XTNT Xtant Medical Holdings Inc.?
The highest price target for XTNT is $1.50 from at , which represents a 235.7% increase from the current price of $0.45.
What is the lowest forecasted price for XTNT Xtant Medical Holdings Inc.?
The lowest price target for XTNT is $1.00 from at , which represents a 123.8% increase from the current price of $0.45.
What is the overall XTNT consensus from analysts for Xtant Medical Holdings Inc.?
The overall analyst consensus for XTNT is bullish. Out of 1 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $1.20.
How accurate are XTNT stock price projections?
Stock price projections, including those for Xtant Medical Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 3:14 AM UTC